MRNA Stock Approaching 52-Week High

Moderna shares rose 5.4% this afternoon to a price of $140.02. The stock is still trading within range of its average target price of $137.59, and over the last 52 weeks, it has recorded a 4.9% performance. Analysts have given the Large-Cap Biotechnology stock target prices ranging from $60.0 to $310.0 dollars per share, with an average rating of buy.

Moderna has an average level of shares sold short, at 7.2% of its total share float. The stock's short ratio (also called days to cover) is 6.93. The company's insiders own 9.59% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Institutional investors own 73.1% of Moderna's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Moderna

Date Reported Holder Percentage Shares Value
2024-03-31 Baillie Gifford and Company 12% 44,655,817 $6,252,707,687
2024-03-31 Vanguard Group Inc 10% 39,036,872 $5,465,942,984
2024-03-31 Blackrock Inc. 7% 25,395,878 $3,555,930,946
2024-03-31 State Street Corporation 4% 14,452,035 $2,023,574,002
2024-03-31 FMR, LLC 4% 13,599,837 $1,904,249,234
2024-03-31 Flagship Pioneering Inc. 3% 9,666,038 $1,353,438,682
2024-03-31 Theleme Partners LLP 2% 7,321,797 $1,025,198,047
2024-03-31 Geode Capital Management, LLC 2% 6,750,479 $945,202,098
2024-03-31 Wellington Management Group, LLP 1% 5,604,703 $784,770,538
2024-03-31 Morgan Stanley 1% 5,493,965 $769,265,002
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.